NeutroSpec Side Effects May Lead To Cardiac Arrest Lawsuits
NeutroSpec | Lawsuits, Lawyers | Side Effects: Cardiopulmonary Failure, Cardiac Arrest, Hypoxia, Dyspnea, Hypotension
NeutroSpec is a radio-pharmaceutical imaging agent approved in the United States for the diagnosis of equivocal appendicitis has been removed from the market. The manufacturer, Palatin Technologies Inc. and marketing partner, Mallinckrodt, removed NeutroSpec after the FDA said the drug can cause severe, life-threatening reactions in some people. NeutroSpec is injected into a patient's bloodstream to help doctors diagnose ailments.
The companies said that two deaths attributed to cardiopulmonary failure, and additional cases of serious cardiopulmonary events, including cardiac arrest, hypoxia, dyspnea, and hypotension, occurred within 30 minutes of their injection with NeutroSpec. The majority of the reactions occurred in patients with underlying cardiopulmonary disease who received NeutroSpec for unapproved indications. Physicians often prescribe approved medications for off-label use.
NeutroSpec, approved for marketing in July 2004, is a diagnostic imaging agent that is administered intravenously to help diagnose appendicitis in patients five years and older with possible appendicitis who do not show the conventional signs and symptoms. The FDA said the decision to suspend marketing was based on the life-threatening nature of the adverse events, the unpredictability of the reaction, and availability of other means of diagnosing appendicitis that do not carry these risks.
Legal Help For Victims Of NeutroSpec
If you or a loved were administered NeutroSpec and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney or Call us anytime at 1-800-YOURLAWYER (1-800-968-7529).